LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Within-trial cost-effectiveness of novel macrophage-regulating treatment on wound healing in patients with diabetic foot ulcers.J Food Drug Anal | PMID 40202410PMC12039530 | 2025-Mar-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.Lancet | PMID 40086461PMC12555891 | 2025-Mar-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.Europace | PMID 40132102PMC11992556 | 2025-Mar-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling.J Med Internet Res | PMID 40153795PMC11992497 | 2025-Mar-28 | 0.90 | The study is a Phase III RCT with drug intervention and reports original results. However, the primary efficacy endpoint is relative dose intensity (a dose-metric), and the analyzed outcomes are toxicity, hospitalization, and emergency visits (safety/clinical endpoints), none of which are time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria.Europace | PMID 40295782PMC12037275 | 2025-Mar-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inebilizumab for Treatment of IgG4-Related Disease.N Engl J Med | PMID 39541094无 PMCID | 2025-Mar-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39660834无 PMCID | 2025-Mar-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.N Engl J Med | PMID 40106374无 PMCID | 2025-Mar-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.Eur J Cancer | PMID 39999670无 PMCID | 2025-Mar-26 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.Eur J Cancer | PMID 40010134无 PMCID | 2025-Mar-26 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40010135无 PMCID | 2025-Mar-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。 | PMID 40122906PMC11930952 | 2025-Mar-23 | 0.85 | This is a Phase III randomized clinical trial in oncology (nasopharyngeal carcinoma) with a drug intervention (Ulinastatin) and reports original results on both the primary endpoint (incidence of grade ≥3 RTOM) and key secondary time-to-event efficacy endpoints (OS, LRRFS, DMFS, PFS) at 3 years. The drug is not a generic/biosimilar and is administered in conjunction with standard chemoradiotherapy. | 无 KM 图 |
| Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19.Toxins (Basel) | PMID 40278658PMC12031167 | 2025-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIG 1.:非 KM 图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图。 | PMID 39591551PMC11936476 | 2025-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.J Clin Oncol | PMID 39621965无 PMCID | 2025-Mar-20 | 0.95 | The trial is a Phase III randomized study with a drug intervention and reports original results, but its primary and key secondary endpoints are complete response rates (non-vomiting/no rescue) for chemotherapy-induced nausea and vomiting prevention. These are categorical efficacy outcomes, not time-to-event endpoints such as overall survival, progression-free survival, or disease-free survival. There is no indication of Kaplan-Meier analysis or hazard ratios for a time-to-event outcome. | 待处理 |
| Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.J Clin Oncol | PMID 39693584无 PMCID | 2025-Mar-20 | 0.95 | Excluded because the trial compares two non-drug interventions (RFA vs. SBRT) and lacks a drug-containing arm, which is a required criterion for eligibility. | 待处理 |
| Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.J Clin Oncol | PMID 39693591PMC11936477 | 2025-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.J Clin Oncol | PMID 39700442PMC11908887 | 2025-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG A1.:非 KM 图;FIG A2.:非 KM 图。 | PMID 39772655PMC11936473 | 2025-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.Vaccine | PMID 39919447无 PMCID | 2025-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.Vaccine | PMID 39923547无 PMCID | 2025-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.J Neurol | PMID 40105996PMC11923026 | 2025-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sonolysis during carotid endarterectomy: randomised controlled trial.BMJ | PMID 40107675PMC11921150 | 2025-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).Br J Dermatol | PMID 39442013无 PMCID | 2025-Mar-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.Br J Dermatol | PMID 39611771无 PMCID | 2025-Mar-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.Br J Dermatol | PMID 39708367无 PMCID | 2025-Mar-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.J Am Coll Cardiol | PMID 40074465无 PMCID | 2025-Mar-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.J Clin Endocrinol Metab | PMID 38824910PMC11913103 | 2025-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy.Clin Infect Dis | PMID 39219495PMC11912963 | 2025-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.J Infect Dis | PMID 39302855PMC11911792 | 2025-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.J Clin Endocrinol Metab | PMID 39376010PMC11913112 | 2025-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.Aesthet Surg J | PMID 39587780PMC11913111 | 2025-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.BMC Cancer | PMID 40098083PMC11916207 | 2025-Mar-17 | 0.85 | While the study meets criteria for oncology, human subjects, randomization, Phase III, drug intervention, and original results, it lacks the required time-to-event efficacy endpoint. The primary endpoint is duration of neutropenia, a toxicity measure, not a survival or progression-free survival endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | 待处理 |
| Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39551103无 PMCID | 2025-Mar-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.Neuropharmacology | PMID 39708914无 PMCID | 2025-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.J Bone Miner Res | PMID 39791502PMC11909733 | 2025-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.Lancet | PMID 40023176无 PMCID | 2025-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.Lancet | PMID 40037388无 PMCID | 2025-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.Int J Mol Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:非 KM 图;Figure 4:非 KM 图;Figure 5:非 KM 图。 | PMID 40141282PMC11942273 | 2025-Mar-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.Am J Gastroenterol | PMID 40079470PMC12282592 | 2025-Mar-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiotherapy quality assurance in the PROTECT trial - a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer.Acta Oncol | PMID 40079654PMC11931855 | 2025-Mar-13 | 0.75 | The record describes the quality assurance programme for a phase III randomized trial in esophageal cancer but does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. It is a methodological report on trial conduct, not a clinical efficacy report. | 待处理 |
| Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.Toxins (Basel) | PMID 40137906PMC11946516 | 2025-Mar-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Negative Pressure Dressings to Prevent Surgical Site Infection After Emergency Laparotomy: The SUNRRISE Randomized Clinical Trial.JAMA | PMID 39869330PMC11773404 | 2025-Mar-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.JAMA | PMID 39908052PMC11800124 | 2025-Mar-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39923274无 PMCID | 2025-Mar-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39952149无 PMCID | 2025-Mar-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.J Clin Oncol | PMID 39378385PMC11895827 | 2025-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:非 KM 图;FIG 3.:非 KM 图。 | PMID 39752608PMC12124660 | 2025-Mar-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.Oncologist疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1.:非 KM 图。 | PMID 40163688PMC11957243 | 2025-Mar-10 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).Radiat Oncol | PMID 40059195PMC11890525 | 2025-Mar-09 | 0.95 | This is a protocol quality assurance (dummy run) report for a randomized phase III trial. It does not report any efficacy outcomes (e.g., survival, progression) required for eligibility. Therefore, it is excluded. | 待处理 |